Bullet fragment fiducials in stereotactic body radiotherapy as a bridge to transplant for hepatocellular carcinoma

Stereotactic ablative body radiotherapy for hepatocellular carcinoma or cholangiocarcinoma

Conformal and stereotactic radiotherapy in hepatocellular carcinoma.

Historically, Radiation Therapy (RT) has played a minor role in the treatment of hepatocellular carcinoma, especially because of toxicity related to conventional techniques. However, high radiation doses can now be given safely by means of 3D-conformal techniques and other more specialized techniques. 3D-conformal RT, in which both target definition and treatment planning are based on three-dim...

Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Resulting in a Durable Relapse-Free Survival: A Case Report

The standard of care for localized hepatocellular carcinoma (HCC) is surgical resection. For patients who decline or who are unfit for surgery, stereotactic body radiotherapy (SBRT) is emerging as a viable treatment approach. We present a case of a 77-year-old female in whom an early stage HCC was incidentally discovered. Given her religious edicts as a devout Jehovah's Witness and her subseque...

Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model‐based analysis

The aim of this study is to compare radiofrequency ablation (RFA) with stereotactic body radiotherapy (SBRT) for hepatocellular carcinomas (HCC) smaller than 3 cm. A Markov cohort model was developed to simulate a cohort of patients aged 60-65 years with small HCCs who had undergone either RFA or SBRT and were followed up over their remaining life expectancy. The inclusion criteria were: (1) HC...

Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies.

AIMS To determine the feasibility and efficacy of stereotactic body radiotherapy (SBRT) for huge hepatocellular carcinoma unsuitable for other therapies. METHODS Six patients with very large hepatocellular carcinomas (>10 cm) unsuitable for surgical resection or that failed to respond to transcatheter arterial chemoembolization (TACE) were treated by SBRT. Doses ranged from 32 Gy to 40 Gy in ...